Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer

Abstract Patients with EGFR mutations in non-small cell lung cancer (NSCLC) have been greatly benefited from gefitinib, however, the therapeutic has failed due to the presence of acquired resistance. In this study, we show that gefitinib significantly induces downregulation of Sterol Regulator Eleme...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Chuncao Xu, Lei Zhang, Daifei Wang, Shiqin Jiang, Di Cao, Zhongxiang Zhao, Min Huang, Jing Jin
Format: article
Langue:EN
Publié: Nature Publishing Group 2021
Sujets:
Accès en ligne:https://doaj.org/article/789b9afc2a3142cea1af59cbc141d0a2
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!